Become A Featured Company

Medical Cannabis: Cancer Cure or Just a Placebo?

Ryan Allway

February 24th, 2016

Exclusive, Policy, Top Story

The federal government began to restrict the use of medical marijuana in the 1930s, against the recommendation of the American Medical Association, beginning a decades-long fight between patients and lawmakers. With widespread recreational consumption in the 1960s, the drug developed a negative connotation throughout mainstream society. People found themselves unable to distinguish between the recreational and the medical side of the drug.

Of course, opioids are widely abused by recreational drug users and come with far harsher side effects, but the consumption of these drugs is rarely in public and scantly publicized. The opioid industry also benefits from the support of multibillion dollar corporations that have successfully lobbied both governments and doctors. By comparison, the cannabis industry is widely unable to fund the basic research under draconian laws, much less invest in marketing.

“There have been significant limitations on these studies in the United States thus far because one needs a Controlled Substance License,” explains Stu Titus, CEO of Medical Marijuana Inc. (OTCQB: MJNA), a publicly traded company that’s studying the use of cannabis for medicinal purposes. “These were infrequently granted, however, now there is an easier path to potentially study CBDs and other cannabinoids and engage in clinical studies.”

The Drug Enforcement Administration (DEA) announced late last year that it would ease some of the regulatory requirements for those who are conducting FDA-approved clinical trials on non-psychoactive CBDs. The modifications are designed to foster ongoing scientific studies assessing the cannabinoid’s potential medicinal value without worrying about a crackdown by law enforcement that has become all-too-common in the community.

Research Shows Promise

The scientific community relies on robust clinical trials to prove safety and efficacy before a drug is released to the public. With these clinical trials becoming easier to conduct, a growing body of evidence has shown that cannabis could be effective in treating serious medical conditions like cancer. However, there’s still much work to be done and patients shouldn’t jump to any immediate conclusion based solely on early clinical studies.

In a 2011 study, researchers showed that CBD down-regulated a gene associated with aggressive human breast cancer. The same study then looked at the effects of CBDs in mouse models and found that the compound significantly reduced primary tumor mass as well as the size and number of lung metastatic foci in two models of metastasis. With limited treatments for aggressive breast cancer, non-toxic CBDs could be a highly beneficial alternative treatment.

The benefits of cannabis may not be limited to CBDs, however. In a 2007 study, researchers showed that THC inhibited tumor growth in non-small cell lung cancer lines. The researchers conducted mouse studies in-vivo and found that THC had an anti-proliferative and anti-angiogenic effect on tumors. THC could therefore be a promising and novel agent for controlling the growth and metastasis of certain lung cancers.

A 2013 study showed that pure cannabinoids and extracts had pro-apoptotic effects on prostate cancer cells both in-vitro and in-vivo. Additional studies have shown potential in treating blood cancers, oral cancer, liver cancer, pancreatic cancer, and a wide array of other cancers, although all of these remain at early stages. With the doors open to CBD trials, this kind of research should be able to progress more quickly moving forward.

Benefits & Drawbacks

Cannabis is unique in this indication because in-vivo human data is widely available given the widespread usage of the drug. As a result, there’s potentially less of a hurdle to overcome when it comes to demonstrating safety, which often comprises Phase I clinical studies. This means that success in pre-clinical trials could point to a rapid move to Phase II clinical trials that could become licensed drugs a lot more quickly than traditional pharmaceutical compounds.

While the early research looks promising, it’s important to note that most studies haven’t been conducted in-vivo in humans. Mice are genetically very similar to humans, but there are many examples of pharmaceuticals that showed tremendous promise in mice and in-vitro human studies, but ultimately failed to achieve clinical outcomes in Phase III clinical trials. The good news is that these pivotal studies could come sooner rather than later.

It’s also worth noting that smoking anything is carcinogenic, albeit at differing levels depending on the substance. Cannabis oils are an alternative form of obtaining cannabinoids, which doesn’t suffer from these effects. Companies like Vape Holdings Inc. (OTCQB: VAPE) are developing their own brand of CBD oil that’s compatible with their vaporizer products in order to help make these compounds more readily available.

Self-medicating may not have the same benefits as clinical trials, however, since the concentrates of cannabinoids and delivery mechanisms differ. In fact, some studies have shown that the absorption of cannabinoids differs widely between users, which means that an effective delivery mechanism may be necessary for in-vivo therapeutics to achieve the same level activation as in-vitro studies see in cell cultures.

Looking Ahead

Cannabis has been demonized since the 1930s, but lawmakers are finally starting to relax their regulations. With a growing body of research showing early promise, cannabis could become a wider field of study for cancer indications. The good news is that safety is already out of the way to a large extent, which could expedite the approval processes for these drugs. In many ways, the government remains the biggest barrier to these advancements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading